Transcat (TRNS) investor relations material

Corporate overview and strategy

• Industry leader in accredited calibration services and equipment, serving mission-critical sectors with a strong recurring revenue model and top-tier margins.

• Operates 35 ISO/IEC 17025:2017 accredited labs, with a 69%/31% service/distribution revenue split in Q4 FY26.

• Focuses on regulated, high-barrier industries like life sciences, aerospace, and defense, with 68 consecutive quarters of YoY service revenue growth.

• Blue-chip customer base includes 19 of the top 20 pharmaceutical companies and major industrial clients.

• Strategic growth driven by recurring revenue, operating leverage, acquisitions, and a strong balance sheet.

Revenue and financial performance

• Q4 FY26 revenue grew 16% YoY to $89.3M; full-year revenue up 19% to $331.9M.

• Service segment revenue increased 18% in Q4 and 20% for the year, with organic growth of 7% in Q4.

• Distribution segment revenue grew 11% in Q4 and 18% for the year, driven by rental demand.

• Q4 consolidated gross profit rose 18% to $30.5M, with gross margin expanding to 34.1%.

• Full-year adjusted EBITDA reached $48.7M, up 23%, with a margin of 14.7%.

Business model and growth drivers

• Recurring, regulatory-driven demand ensures predictable revenue and resilience through economic cycles.

• Strategic shift from distribution to higher-margin service segment, now 65% of revenue.

• Cross-selling between distribution and calibration services accelerates growth and margin expansion.

• Focused on high-growth, regulated verticals with high switching costs and long qualification cycles.

• International expansion through acquisitions, now operating in the US, Canada, Ireland, and Latin America.